Zdrowie i gospodarka · 05/12/2013

FDA Releases Draft Guidance on Bioequivalence Studies for ANDA Submissions

The FDA has published a draft guidance for industry on conducting bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an Abbreviated New Drug Application (ANDA), aiming to help applicants meet regulatory requirements for abbreviated new drug applications.